The Effect of Hepatic Impairment on the Pharmacokinetics of Dacomitinib

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

ISSN: 1179-1918

Extent: Online-Ressource

Language: Englisch

Notes: online resource.

Bibliographic citation: The Effect of Hepatic Impairment on the Pharmacokinetics of Dacomitinib ; volume:42 ; number:3 ; day:23 ; month:2 ; year:2022 ; pages:221-235 ; date:3.2022
Clinical drug investigation ; 42, Heft 3 (23.2.2022), 221-235, 3.2022

Creator: Piscitelli, Joseph
Chen, Joseph
LaBadie, Robert R.
Salageanu, Joanne
Chung, Chin-Hee
Tan, Weiwei

Contributor: SpringerLink (Online service)

DOI: 10.1007/s40261-022-01125-x

URN: urn:nbn:de:101:1-2022060920322903795007

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 03.04.2025, 2:52 PM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Piscitelli, Joseph
Chen, Joseph
LaBadie, Robert R.
Salageanu, Joanne
Chung, Chin-Hee
Tan, Weiwei
SpringerLink (Online service)

Other Objects (12)

Effect of hepatic or renal impairment on the pharmacokinetics of evacetrapib

The Pharmacokinetics and Safety of Tucatinib in Volunteers with Hepatic Impairment

Influence of mild and moderate hepatic impairment on axitinib pharmacokinetics

Effect of Age, Sex, Renal Impairment and Hepatic Impairment on the Safety, Pharmacokinetics and Pharmacodynamics of Asundexian

Brigatinib pharmacokinetics in patients with chronic hepatic impairment

Pharmacokinetics of the soluble guanylate cyclase stimulator riociguat in individuals with hepatic impairment

Pharmacokinetics and safety of niraparib in patients with moderate hepatic impairment

Pharmacokinetics of afatinib in subjects with mild or moderate hepatic impairment

Effects of Hepatic Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide

Simulating Healthy Participant Pharmacokinetics for Renal and Hepatic Impairment Studies: Retrospective Assessment of the Approach

Pharmacokinetics of the Novel Nonsteroidal Mineralocorticoid Receptor Antagonist Ocedurenone (KBP-5074) in Individuals with Moderate Hepatic Impairment

Pharmacokinetics and safety of rucaparib in patients with advanced solid tumors and hepatic impairment

Effect of hepatic or renal impairment on the pharmacokinetics of evacetrapib

The Pharmacokinetics and Safety of Tucatinib in Volunteers with Hepatic Impairment

Influence of mild and moderate hepatic impairment on axitinib pharmacokinetics

Effect of Age, Sex, Renal Impairment and Hepatic Impairment on the Safety, Pharmacokinetics and Pharmacodynamics of Asundexian

Brigatinib pharmacokinetics in patients with chronic hepatic impairment

Pharmacokinetics of the soluble guanylate cyclase stimulator riociguat in individuals with hepatic impairment

Pharmacokinetics and safety of niraparib in patients with moderate hepatic impairment

Pharmacokinetics of afatinib in subjects with mild or moderate hepatic impairment

Effects of Hepatic Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide

Simulating Healthy Participant Pharmacokinetics for Renal and Hepatic Impairment Studies: Retrospective Assessment of the Approach

Pharmacokinetics of the Novel Nonsteroidal Mineralocorticoid Receptor Antagonist Ocedurenone (KBP-5074) in Individuals with Moderate Hepatic Impairment

Pharmacokinetics and safety of rucaparib in patients with advanced solid tumors and hepatic impairment

Effect of hepatic or renal impairment on the pharmacokinetics of evacetrapib

The Pharmacokinetics and Safety of Tucatinib in Volunteers with Hepatic Impairment

Influence of mild and moderate hepatic impairment on axitinib pharmacokinetics

Effect of Age, Sex, Renal Impairment and Hepatic Impairment on the Safety, Pharmacokinetics and Pharmacodynamics of Asundexian

Brigatinib pharmacokinetics in patients with chronic hepatic impairment

Pharmacokinetics of the soluble guanylate cyclase stimulator riociguat in individuals with hepatic impairment

Pharmacokinetics and safety of niraparib in patients with moderate hepatic impairment

Pharmacokinetics of afatinib in subjects with mild or moderate hepatic impairment

Effects of Hepatic Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide

Simulating Healthy Participant Pharmacokinetics for Renal and Hepatic Impairment Studies: Retrospective Assessment of the Approach

Pharmacokinetics of the Novel Nonsteroidal Mineralocorticoid Receptor Antagonist Ocedurenone (KBP-5074) in Individuals with Moderate Hepatic Impairment

Pharmacokinetics and safety of rucaparib in patients with advanced solid tumors and hepatic impairment

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

The Effect of Hepatic Impairment on the Pharmacokinetics of Dacomitinib

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Effect of hepatic or renal impairment on the pharmacokinetics of evacetrapib

The Pharmacokinetics and Safety of Tucatinib in Volunteers with Hepatic Impairment

Influence of mild and moderate hepatic impairment on axitinib pharmacokinetics

Effect of Age, Sex, Renal Impairment and Hepatic Impairment on the Safety, Pharmacokinetics and Pharmacodynamics of Asundexian

Brigatinib pharmacokinetics in patients with chronic hepatic impairment

Pharmacokinetics of the soluble guanylate cyclase stimulator riociguat in individuals with hepatic impairment

Pharmacokinetics and safety of niraparib in patients with moderate hepatic impairment

Pharmacokinetics of afatinib in subjects with mild or moderate hepatic impairment

Effects of Hepatic Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide

Simulating Healthy Participant Pharmacokinetics for Renal and Hepatic Impairment Studies: Retrospective Assessment of the Approach

Pharmacokinetics of the Novel Nonsteroidal Mineralocorticoid Receptor Antagonist Ocedurenone (KBP-5074) in Individuals with Moderate Hepatic Impairment

Pharmacokinetics and safety of rucaparib in patients with advanced solid tumors and hepatic impairment

Effect of hepatic or renal impairment on the pharmacokinetics of evacetrapib

The Pharmacokinetics and Safety of Tucatinib in Volunteers with Hepatic Impairment

Influence of mild and moderate hepatic impairment on axitinib pharmacokinetics

Effect of Age, Sex, Renal Impairment and Hepatic Impairment on the Safety, Pharmacokinetics and Pharmacodynamics of Asundexian

Brigatinib pharmacokinetics in patients with chronic hepatic impairment

Pharmacokinetics of the soluble guanylate cyclase stimulator riociguat in individuals with hepatic impairment

Pharmacokinetics and safety of niraparib in patients with moderate hepatic impairment

Pharmacokinetics of afatinib in subjects with mild or moderate hepatic impairment

Effects of Hepatic Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide

Simulating Healthy Participant Pharmacokinetics for Renal and Hepatic Impairment Studies: Retrospective Assessment of the Approach

Pharmacokinetics of the Novel Nonsteroidal Mineralocorticoid Receptor Antagonist Ocedurenone (KBP-5074) in Individuals with Moderate Hepatic Impairment

Pharmacokinetics and safety of rucaparib in patients with advanced solid tumors and hepatic impairment

Effect of hepatic or renal impairment on the pharmacokinetics of evacetrapib

The Pharmacokinetics and Safety of Tucatinib in Volunteers with Hepatic Impairment

Influence of mild and moderate hepatic impairment on axitinib pharmacokinetics

Effect of Age, Sex, Renal Impairment and Hepatic Impairment on the Safety, Pharmacokinetics and Pharmacodynamics of Asundexian

Brigatinib pharmacokinetics in patients with chronic hepatic impairment

Pharmacokinetics of the soluble guanylate cyclase stimulator riociguat in individuals with hepatic impairment

Pharmacokinetics and safety of niraparib in patients with moderate hepatic impairment

Pharmacokinetics of afatinib in subjects with mild or moderate hepatic impairment

Effects of Hepatic Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide

Simulating Healthy Participant Pharmacokinetics for Renal and Hepatic Impairment Studies: Retrospective Assessment of the Approach

Pharmacokinetics of the Novel Nonsteroidal Mineralocorticoid Receptor Antagonist Ocedurenone (KBP-5074) in Individuals with Moderate Hepatic Impairment

Pharmacokinetics and safety of rucaparib in patients with advanced solid tumors and hepatic impairment

Related objects

Reset password